![Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies - Cancer Treatment Reviews Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies - Cancer Treatment Reviews](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/88c33a30-1781-4baa-9eae-b673fc22034a/gr1_lrg.jpg)
Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies - Cancer Treatment Reviews
PLOS ONE: MET exon 14 skipping mutations and gene amplification in a Taiwanese lung cancer population
![Characterization of MET exon 14 alteration and association with clinical outcomes of crizotinib in Chinese lung cancers - Lung Cancer Characterization of MET exon 14 alteration and association with clinical outcomes of crizotinib in Chinese lung cancers - Lung Cancer](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/6d8e24ed-aece-4976-8af5-b185e5b710fc/gr1_lrg.jpg)
Characterization of MET exon 14 alteration and association with clinical outcomes of crizotinib in Chinese lung cancers - Lung Cancer
![MET Exon 14 Skipping Alterations in NSCLC: Current Understanding and Therapeutic Advances - touchONCOLOGY MET Exon 14 Skipping Alterations in NSCLC: Current Understanding and Therapeutic Advances - touchONCOLOGY](https://touchoncology.com/wp-content/uploads/sites/2/2020/12/Fig-2-1.jpg)
MET Exon 14 Skipping Alterations in NSCLC: Current Understanding and Therapeutic Advances - touchONCOLOGY
![The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable - ScienceDirect The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S016950021630527X-gr2.jpg)
The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable - ScienceDirect
![MET Exon 14 Skipping Alterations in NSCLC: Current Understanding and Therapeutic Advances - touchONCOLOGY MET Exon 14 Skipping Alterations in NSCLC: Current Understanding and Therapeutic Advances - touchONCOLOGY](https://touchoncology.com/wp-content/uploads/sites/2/2020/12/Fig-3-1.jpg)
MET Exon 14 Skipping Alterations in NSCLC: Current Understanding and Therapeutic Advances - touchONCOLOGY
![Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration | Nature Medicine Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration | Nature Medicine](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41591-019-0716-8/MediaObjects/41591_2019_716_Fig1_HTML.png)
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration | Nature Medicine
![Prevalence of MET exon 14 skipping mutation in pulmonary sarcomatoid carcinoma patients without common targetable mutations: A single-institute study Yu Y, Zhang Q, Zhang J, Lu S - J Can Res Ther Prevalence of MET exon 14 skipping mutation in pulmonary sarcomatoid carcinoma patients without common targetable mutations: A single-institute study Yu Y, Zhang Q, Zhang J, Lu S - J Can Res Ther](https://www.cancerjournal.net/articles/2019/15/4/images/JCanResTher_2019_15_4_909_264294_i4.jpg)
Prevalence of MET exon 14 skipping mutation in pulmonary sarcomatoid carcinoma patients without common targetable mutations: A single-institute study Yu Y, Zhang Q, Zhang J, Lu S - J Can Res Ther
![The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping - Cancer Treatment Reviews The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping - Cancer Treatment Reviews](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2f846160-b4c3-44f1-82de-648c25ad83e0/gr1_lrg.jpg)
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping - Cancer Treatment Reviews
![Optimization of Routine Testing for MET Exon 14 Splice Site Mutations in NSCLC Patients - ScienceDirect Optimization of Routine Testing for MET Exon 14 Splice Site Mutations in NSCLC Patients - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1556086418330387-gr2.jpg)
Optimization of Routine Testing for MET Exon 14 Splice Site Mutations in NSCLC Patients - ScienceDirect
![Introduction - Targeting METex14 NSCLC - Text Module - MET Inhibition in NSCLC - Oncology - Clinical Care Options Introduction - Targeting METex14 NSCLC - Text Module - MET Inhibition in NSCLC - Oncology - Clinical Care Options](https://www.clinicaloptions.com/-/media/oncology/programs/nsclc-metex14/module-thumbs/cco-metex14-asco-cf_thumb2.png?rev=5b312d1500fb430198a84dee8244cc96)
Introduction - Targeting METex14 NSCLC - Text Module - MET Inhibition in NSCLC - Oncology - Clinical Care Options
PLOS ONE: MET exon 14 skipping mutations and gene amplification in a Taiwanese lung cancer population
![Figure 2 from MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression. | Semantic Scholar Figure 2 from MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/63e4b99a551c5b6051e8d2ab1eb946039d127902/5-Figure2-1.png)
Figure 2 from MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression. | Semantic Scholar
![MET Exon 14 Skipping Mutation in Non-Small Cell Lung Cancer Identified by Anchored Multiplex PCR and Next- Generation Sequencing MET Exon 14 Skipping Mutation in Non-Small Cell Lung Cancer Identified by Anchored Multiplex PCR and Next- Generation Sequencing](https://www.primescholars.com/articles-images/cancer-epidemiology-prevention-Integrated-Genome-Viewer-1-1-1-g001a.png)
MET Exon 14 Skipping Mutation in Non-Small Cell Lung Cancer Identified by Anchored Multiplex PCR and Next- Generation Sequencing
![Molecular Diagnostic Assays and Clinicopathologic Implications of MET Exon 14 Skipping Mutation in Non–small-cell Lung Cancer - Clinical Lung Cancer Molecular Diagnostic Assays and Clinicopathologic Implications of MET Exon 14 Skipping Mutation in Non–small-cell Lung Cancer - Clinical Lung Cancer](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/df0dbf25-b023-4553-9f6b-87905379ae01/gr1.jpg)
Molecular Diagnostic Assays and Clinicopathologic Implications of MET Exon 14 Skipping Mutation in Non–small-cell Lung Cancer - Clinical Lung Cancer
![MET Exon 14 Skipping Alterations in NSCLC: Current Understanding and Therapeutic Advances - touchONCOLOGY MET Exon 14 Skipping Alterations in NSCLC: Current Understanding and Therapeutic Advances - touchONCOLOGY](https://touchoncology.com/wp-content/uploads/sites/2/2020/12/Fig-1-1.jpg)
MET Exon 14 Skipping Alterations in NSCLC: Current Understanding and Therapeutic Advances - touchONCOLOGY
![Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer - Lung Cancer Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer - Lung Cancer](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/5132f241-0043-4f04-ac34-e795a10d6132/gr1_lrg.jpg)